Amarin Corporation (AMRN) Proxy Filing summary

Executive summary

• 2024 saw a new permanent CEO appointed, a focused commercial strategy in Europe, and continued U.S. profitability with a strong cash position and no debt at year-end.

• The company is prioritizing European and global expansion, maintaining financial discipline, and supporting research for its lead product, VASCEPA/VAZKEPA.

• The Board and management are committed to unlocking global potential and maximizing shareholder value, with a focus on long-term growth.

Voting matters and shareholder proposals

• Shareholders will vote on the re-election of eight directors, an advisory say-on-pay vote, auditor appointment, authority to allot shares, and disapplication of pre-emptive rights.

• All directors are now subject to annual re-election following the elimination of the classified board structure.

• The Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• The Board is majority independent, with only the CEO considered non-independent.

• All key committees (Audit, Remuneration, Nominating and Corporate Governance) are composed solely of independent directors.

• The Board holds regular meetings of independent directors and encourages director attendance at annual meetings.

• Director and executive stock ownership guidelines are in place to align interests with shareholders.